Pfizer Informs Nebraska to Not use its drugs in Implementation

Pharmaceutical company Pfizer is demanding that Nebraska yield any medication manufactured by the business or an affiliate which the state intends to use in an implementation.

State prison officials announced last week that it intends to use a new combination of four drugs in the implementation of death-row inmate Jose Sandoval. No execution date has been set.

In an Oct. 4 letter, Pfizer said it “strongly objects to the use of its products as lethal injections for capital punishment,” the Omaha World-Herald reported . The letter was one of many documents released by the state Department of Corrections this week in reaction to public records requests from The World-Herald along with the ACLU of Nebraska.

The organization adopted a policy in 2016 that prohibited the use of its products and those of its affiliate, Hospira, in an implementation. The 13 restricted products are meant to improve and save lives, not take them, the company said.

Pfizer said it will reimburse the state for any medication it returns.

Officials with the Nebraska Department of Correctional Services and the office of Gov. Pete Ricketts diminished state whether the state has any Pfizer drugs.

The state spent $10,500 final month on four medications for the implementation, said Dawn-Renee Smith, a spokeswoman for the corrections department. While Smith did not disclose the source of the drugs, she said they did come from a source in the U.S.

Nebraska intends to use diazepam, commonly called Valium; synthetic opioid fentanyl citrate; paralytic cisatracurium besylate; and potassium chloride in its lethal injections.

Pfizer produces three of the four medications, with cisatracurium besylate as the exception, according to a Pfizer spokesman.

Nebraska has struggled to acquire lethal injection drugs in recent years due to company bans.

Voters reinstated capital punishment this past year, overriding state lawmakers who had abolished the death penalty. Nebraska has not executed anyone since 1997.

Courtesy: The Globe And Mail

Leave a Reply

Your email address will not be published. Required fields are marked *